Peptide

Retatrutide (triple agonist)

Prescription drug.

Regulatory status

In clinical trials

FDA (U.S.): Not approved. In phase 3 (TRIUMPH program); Lilly expects to apply for U.S. approval in the first quarter of 2027 (press release, Jul 23, 2026).

EMA (EU): Not approved (no authorization; Lilly announces global submissions for obesity, knee pain from osteoarthritis, and sleep apnea).

How to take it

There is no established standard dose for this case; it is advisable to consult a professional.

Safety

Investigational drug; prescription.

Effect by goal · level of evidence

Obesity (weight loss)

reduces Moderate study (A)

24%

Phase 2 trial: retatrutide (GIP/GLP-1/glucagon triple agonist) produced very large weight losses (up to ~24% at high doses) in people with obesity. Striking results, still under investigation. Drug in development, prescription.

View the study (study) →

In depth

Drug · Highest evidence: Moderate · 1 finding

⚠️ Investigational drug; prescription only.

Findings

Obesity (weight loss) — reduces (Moderate, study). Phase 2 trial: retatrutide (a triple GIP/GLP-1/glucagon agonist) produced very large weight losses (up to ~24% at high doses) in people with obesity. Striking results, still under investigation. Drug in development, prescription only. 37366315

Information, not medical advice. Prescription drugs require a doctor.

Information, not medical advice. Scientific evidence reflects the quality of the studies.